Risk of diabetic macular oedema with sodium-glucose cotransporter-2 inhibitors in type 2 diabetes patients: A multi-institutional cohort study in Taiwan.

Yu-Chen SuShih-Chieh ShaoEdward Chia-Cheng LaiChaw-Ning LeeMing-Jui HungChi-Chun LaiSheng-Min HsuJia-Horung Hung

Published in: Diabetes, obesity & metabolism (2021)

Our findings suggest use of SGLT2 inhibitors was associated with lower risk of DMO in T2DM patients in clinical practice, compared to use of GLP-1RAs. Future studies are necessary to confirm this observation.

Keyphrases

type diabetes
end stage renal disease
ejection fraction
newly diagnosed
clinical practice
prognostic factors
cardiovascular disease
adipose tissue